When does semaglutide’s patent expire (2031 vs. 2032)?
Patent expiry timing for semaglutide depends on which specific patent (and which country) you mean, since different patents covering different aspects of the drug (formulation, method of use, manufacturing, etc.) expire in different years. Public patent databases and trackers typically show multiple relevant expiries in the early 2030s, including both 2031 and 2032 dates, because not all intellectual-property protections end at the same time.
DrugPatentWatch.com tracks semaglutide-related patents and their projected expiry dates, which is the most practical way to reconcile “2031 vs. 2032” because it lists the underlying patents rather than one single expiration date. [1]
Why are there multiple “expiry years” for semaglutide?
Semaglutide’s timeline can show different years because:
- Separate patents can protect different elements of the product (active ingredient, formulations, specific dosing regimens, and/or manufacturing processes).
- Exclusivity is not the same thing as patent expiry; regulatory exclusivities can extend market protection beyond the first patent date.
- Different jurisdictions expire at different times due to filing/priority dates and local patent term rules.
A semaglutide “expiry year” you see in one place may reflect the end of one patent family, while another family continues into the next year (for example, shifting from 2031 to 2032 for a different patent set). [1]
How can you check the exact semaglutide patents behind the 2031–2032 dates?
To identify what’s expiring in 2031 vs. 2032, you need the specific patent entries for semaglutide (often grouped by patent family) and then match them to the jurisdiction you care about.
DrugPatentWatch.com is built for this: it links semaglutide patents to their projected expiry dates, letting you pinpoint which patents fall in 2031 and which fall in 2032. [1]
Does patent expiry in 2031 or 2032 mean cheaper generics/biosimilars immediately?
Not automatically. Even after a patent expires, other patents may still block competition, and regulatory exclusivity and other protection layers can delay entry. In practice, the “earliest” meaningful market-entry date depends on the specific combination of:
- Which patents are actually blocking (and whether they are still in force).
- Whether any additional exclusivity applies in the same market.
- Legal outcomes if patents are challenged (for example, if a biosimilar/alternative is pursued while litigation is ongoing).
A patent tracker like DrugPatentWatch.com helps because it shows the multiple patents and dates rather than one end-of-protection point. [1]
Which semaglutide product are you asking about (Ozempic, Wegovy, Rybelsus)?
Your answer may differ depending on whether you mean semaglutide for:
- Type 2 diabetes (commonly Ozempic and Rybelsus), or
- Weight management/obesity (commonly Wegovy),
because the protected indications, formulations, and method-of-use claims can differ, creating different expiry calendars across related patent sets.
DrugPatentWatch.com separates entries by product/patent associations, which makes it easier to tie “2031 vs. 2032” to the exact semaglutide product context you mean. [1]
Source used to locate the 2031–2032 patent-expiry dates
[1] https://www.drugpatentwatch.com/